Marine microalgae composition for preventing and / or improving acute stomach injury, special diet, preparation method and application

Abstract

The invention provides a marine microalgae composition for preventing and / or improving acute stomach injury, a special diet, a preparation method and application, and relates to the technical field of traditional Chinese medicines. Comprising 20 to 26 parts of wheat oligopeptide, 15 to 24 parts of microalgae, 5 to 10 parts of dandelion, 4 to 8 parts of Chinese yam, 1 to 5 parts of orange peel, 2 to 4 parts of jujube, 0.5 to 1.5 parts of white hyacinth bean, 1 to 2 parts of hawthorn, 0.5 to 2 parts of poria cocos, 0.4 to 1.2 parts of endothelium corneum gigeriae galli, 0.3 to 0.8 part of malt, 1 to 2 parts of liquorice, 0.2 to 0.6 part of radish seed, 0.5 to 1.5 parts of ginger, 5 to 8 parts of ginseng and 0.4 to 2 parts of raspberry. Microalgae, dandelion, Chinese yam, orange peel, jujube, white hyacinth bean, hawthorn, poria cocos, endothelium corneum gigeriae galli, malt, liquorice, semen raphani, ginger and ginseng are used as auxiliary materials and are matched and interacted with wheat oligopeptide, so that the acute stomach injury is prevented and / or improved. All the components are both food and medicine, and homology of medicine and food is achieved.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a marine microalgae composition, a special diet, a preparation method and an application thereof for preventing and / or improving acute gastric injury. Background Art

[0002] Gastrointestinal diseases are one of the global health epidemics. According to statistics, 5%-10% of the world's population suffers from diseases ranging from gastritis to gastric cancer. In my country, there is a saying that nine out of ten people have stomach problems. Epidemiology shows that the incidence of digestive tract-related diseases in drinkers is much higher than that in non-drinkers, and the incidence of acute alcoholic gastric ulcers is more significant. Studies have shown that when mice are given 75% alcohol, it is found that the mouse's gastric tissue has severe lesions, gastric mucosal congestion and necrosis. Ethanol as one of the invasive factors of gastric damage cannot be ignored.

[0003] Gastric ulcer and gastric injury are mainly treated with drugs, such as proton pump inhibitors, antacids, antihistamines, etc., which are difficult to treat. Moreover, the side effects such as liver and kidney damage and abnormal hematopoietic function caused by them hinder the effective use of gastric ulcer drugs. Compared with chemical drugs, Chinese herbal compound has higher safety in treating gastric ulcer, and the active ingredients in Chinese herbal compound also have synergistic effects.

[0004] Therefore, it is urgent to find a safe, effective, and edible substance with few side effects to prevent and improve gastrointestinal diseases such as gastric ulcers and gastric damage.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] One of the purposes of the present invention is to provide a marine microalgae composition for preventing and / or improving acute gastric injury, so as to solve the technical problem of the lack of a medicinal and edible substance that can safely and effectively prevent and / or improve acute gastric injury in the prior art.

[0007] A second object of the present invention is to provide a method for preparing the above-mentioned marine microalgae composition.

[0008] The third object of the present invention is to provide the use of the above-mentioned marine microalgae composition or the marine microalgae composition prepared by the above-mentioned preparation method in the preparation of a product for preventing and / or improving acute gastric injury.

[0009] A fourth object of the present invention is to provide a product for preventing acute gastric injury.

[0010] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0011] In a first aspect, the present invention provides a marine microalgae composition for preventing and / or improving acute gastric injury, comprising the following components in parts by weight: 20-26 parts of wheat oligopeptides, 15-24 parts of microalgae, 5-10 parts of dandelion, 4-8 parts of yam, 1-5 parts of orange peel, 2-4 parts of jujube, 0.5-1.5 parts of white hyacinth bean, 1-2 parts of hawthorn, 0.5-2 parts of poria, 0.4-1.2 parts of chicken gizzard lining, 0.3-0.8 parts of malt, 1-2 parts of licorice, 0.2-0.6 parts of radish seeds, 0.5-1.5 parts of ginger, 5-8 parts of ginseng and 0.4-2 parts of raspberry.

[0012] Furthermore, the invention comprises the following components in parts by weight: 24 parts of wheat oligopeptides, 20 parts of microalgae, 7 parts of dandelion, 6 parts of yam, 3.5 parts of orange peel, 3 parts of jujube, 1 part of white hyacinth bean, 1.6 parts of hawthorn, 1.3 parts of poria, 0.8 parts of chicken gizzard lining, 0.5 parts of malt, 1.5 parts of licorice, 0.4 parts of radish seeds, 1 part of ginger, 6.5 parts of ginseng and 1.3 parts of raspberry.

[0013] Furthermore, the microalgae is at least one of Dunaliella salina, Pseudo-Nanochloa, Haematococcus pluvialis, Spirulina or Chlorella.

[0014] In a second aspect, the present invention provides a method for preparing the above-mentioned combination, comprising mixing the components according to the formula amount to prepare a marine microalgae composition.

[0015] Furthermore, before mixing, the components are crushed and broken into powder respectively;

[0016] Preferably, the particle size of the powder is 0.01-0.3 mm.

[0017] In a third aspect, the present invention provides use of the marine microalgae composition or the marine microalgae composition prepared by the above preparation method in preparing a product for preventing and / or improving acute gastric injury.

[0018] In a fourth aspect, the present invention provides a product for preventing acute gastric injury, comprising the marine microalgae composition described above or the marine microalgae composition prepared by the above preparation method.

[0019] Furthermore, pharmaceutically and / or food acceptable dressings are also included.

[0020] Furthermore, the pharmaceutically and / or food acceptable excipients;

[0021] Preferably, the pharmaceutically and / or food acceptable excipients are 16 to 23 parts, preferably 18 to 20 parts;

[0022] Preferably, the pharmaceutically and / or food acceptable excipient comprises at least one of maltodextrin, lactose or corn starch, preferably maltodextrin.

[0023] Further, the product is a liquid preparation or a solid preparation;

[0024] Preferably, the solid preparation is a solid beverage;

[0025] Preferably, the product comprises a medicine or a food;

[0026] Preferably, the food product is a special diet.

[0027] The present invention provides a marine microalgae composition for preventing and / or improving acute gastric injury, which is mainly composed of wheat oligopeptides, can improve the damage of gastric mucosal tissue and enhance gastric mucosal protective factors. However, the inventors found that the effect of improving acute gastric injury cannot be achieved by applying wheat oligopeptides alone. Further experiments found that microalgae, dandelion, yam, orange peel, jujube, white hyacinth bean, hawthorn, Poria, chicken gizzard lining, malt, licorice, radish seeds, ginger, and ginseng are used as auxiliary ingredients to be compatible with wheat oligopeptides. Through the interaction of multiple components, acute gastric injury can be prevented and / or improved. At the same time, each component of the marine microalgae composition is both food and medicine, realizing the homology of medicine and food. The technical problem of the lack of materials and techniques of medicine and food homology that can safely and effectively prevent and / or improve acute gastric injury in the prior art is solved. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0029] Figure 1 A comparison chart showing the improvement effect of a marine microalgae composition for preventing and / or improving acute gastric injury provided in Experiment 1 of the present invention on gastric tissue of SD rats with ethanol-induced acute gastric injury;

[0030] Figure 2 This is a comparison of HE staining results of gastric tissue under different treatments provided in Experiment 1 of the present invention;

[0031] Figure 3 This is a comparison of the PAS staining results of gastric tissue under different treatments provided in Experiment 1 of the present invention;

[0032] Figure 4 A comparison chart showing the effect of a marine microalgae composition for preventing and / or improving acute gastric injury provided in Experiment 1 of the present invention on the inflammatory response in the serum of SD rats with ethanol-induced acute gastric injury;

[0033] Figure 5 The levels of oxidative stress biomarkers in rat gastric tissue under different treatments provided in Experiment 1 of the present invention;

[0034] Figure 6 Intersection target for treating gastric injury by a marine microalgae composition for preventing and / or improving acute gastric injury provided in Experiment 2 of the present invention;

[0035] Figure 7 A PPI network diagram of a marine microalgae composition for preventing and / or improving acute gastric injury for treating gastric injury provided in Experiment 2 of the present invention;

[0036] Figure 8 GO enrichment analysis diagram of a marine microalgae composition for preventing and / or improving acute gastric injury for treating gastric injury provided in Experiment 2 of the present invention;

[0037] Fig. 9 A KEGG enrichment analysis diagram of a marine microalgae composition for preventing and / or improving acute gastric injury for treating gastric injury provided in Experiment 2 of the present invention;

[0038] Fig.10 This is a drug-active ingredient-disease-target network diagram for treating gastric injury using a marine microalgae composition for preventing and / or improving acute gastric injury provided in Experiment 2 of the present invention. DETAILED DESCRIPTION

[0039] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention shall have the meanings commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the case of any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definitions. In this application, unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "including" and other forms is non-limiting.

[0040] On the one hand, the present invention provides a marine microalgae composition for preventing and / or improving acute gastric injury, comprising the following components in parts by weight: 20-26 parts of wheat oligopeptides, 15-24 parts of microalgae, 5-10 parts of dandelions, 4-8 parts of yam, 1-5 parts of orange peel, 2-4 parts of jujube, 0.5-1.5 parts of white hyacinth bean, 1-2 parts of hawthorn, 0.5-2 parts of poria, 0.4-1.2 parts of chicken gizzard lining, 0.3-0.8 parts of malt, 1-2 parts of liquorice, 0.2-0.6 parts of radish seeds, 0.5-1.5 parts of ginger, 5-8 parts of ginseng and 0.4-2 parts of raspberry.

[0041] Wheat oligopeptides are mainly used to improve the damage of gastric mucosal tissue and enhance the protective factor of gastric mucosa. However, the inventors found that the effect of improving acute gastric injury cannot be achieved by applying wheat oligopeptides alone. Further experiments found that by using microalgae, dandelion, yam, orange peel, jujube, white hyacinth bean, hawthorn, Poria, chicken gizzard lining, malt, licorice, radish seed, ginger, and ginseng as auxiliary ingredients and wheat oligopeptides, acute gastric injury can be prevented and / or improved through the interaction of multiple components. At the same time, each component of the marine microalgae composition is both food and medicine, realizing the homology of medicine and food. The technical problem of the lack of a substance that can safely and effectively prevent and / or improve acute gastric injury in the prior art is solved.

[0042] The weight proportion of wheat oligopeptide may be, but is not limited to, 20, 21, 22, 23, 24, 25 or 26 parts, and may be any value between 20 and 26 parts.

[0043] The weight proportion of the microalgae may be, but is not limited to, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 parts, or any value between 15 and 24 parts.

[0044] The weight proportion of dandelion can be, but is not limited to, 5, 6, 7, 8, 9 or 10 parts, and can also be any value between 5 and 10 parts.

[0045] The weight proportion of yam may be, but is not limited to, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8 parts, and may be any value between 4 and 8 parts.

[0046] The weight proportion of orange peel can be, but is not limited to, 1, 2, 3, 4, 5 or 6 parts, and can also be any value between 1 and 5 parts.

[0047] The weight proportion of the jujube may be, but is not limited to, 2, 2.5, 3, 3.5 or 4 parts, and may be any value between 2 and 4 parts.

[0048] The weight proportion of white lentil can be, but is not limited to, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5, and can be any value between 0.5 and 1.5.

[0049] The weight proportion of hawthorn may be, but is not limited to, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 parts, and may be any value between 1 and 2 parts.

[0050] The weight proportion of Poria cocos may be, but is not limited to, 0.5, 0.7, 1, 1.2, 1.4, 1.6, 1.8, or 2, and may be any value between 0.5 and 2.

[0051] The weight proportion of chicken gizzard lining can be, but is not limited to, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1 or 1.2 parts, and can also be any value between 0.4 and 1.2 parts.

[0052] The weight proportion of malt may be, but is not limited to, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8, and may be any value between 0.3 and 0.8.

[0053] The weight proportion of licorice can be, but is not limited to, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts or 2 parts, and can also be any value between 1 and 2 parts.

[0054] The weight proportion of radish seeds may be, but is not limited to, 0.2, 0.3, 0.4, 0.5 or 0.6, and may be any value between 0.2 and 0.6.

[0055] The weight proportion of ginger can be, but is not limited to, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5, and can be any value between 0.5 and 1.5.

[0056] The weight proportion of ginseng may be, but is not limited to, 5, 6, 7 or 8 parts, and may be any value between 5 and 8 parts.

[0057] The weight proportion of raspberries may be, but is not limited to, 0.4, 0.5, 0.7, 1, 1.2, 1.4, 1.6, 1.8 or 2, and may be any value between 0.4 and 2.

[0058] In some specific embodiments, the following components are included in parts by weight: 24 parts of wheat oligopeptides, 20 parts of microalgae, 7 parts of dandelion, 6 parts of yam, 3.5 parts of orange peel, 3 parts of jujube, 1 part of white hyacinth bean, 1.6 parts of hawthorn, 1.3 parts of Poria, 0.8 parts of chicken gizzard lining, 0.5 parts of malt, 1.5 parts of licorice, 0.4 parts of radish seeds, 1 part of ginger, 6.5 parts of ginseng and 1.3 parts of raspberry.

[0059] In some specific embodiments, the microalgae is at least one of Dunaliella salina, Nannochloropsis spp., Haematococcus pluvialis, Spirulina or Chlorella.

[0060] According to another aspect of the present invention, a method for preparing the above-mentioned combination is also provided, comprising mixing the components according to the formula amount to prepare the marine microalgae composition.

[0061] In order to facilitate the release of active ingredients, in some specific embodiments, the components are crushed and broken into powder before mixing.

[0062] The particle size of the powder is 0.01 to 0.3 mm. Specifically, the particle size of the powder may be but is not limited to 0.01 mm, 0.03 mm, 0.06 mm, 0.09 mm, 0.1 mm, 0.13 mm, 0.16 mm, 0.19 mm, 0.2 mm, 0.23 mm, 0.26 mm, 0.29 mm or 0.3 mm.

[0063] According to another aspect of the present invention, there is also provided use of the marine microalgae composition or the marine microalgae composition prepared by the above preparation method in preparing a product for preventing and / or improving acute gastric injury.

[0064] Among them, acute gastric injury includes acute simple gastritis, acute erosive gastritis, acute corrosive gastritis or acute suppurative gastritis.

[0065] According to another aspect of the present invention, a product for preventing acute gastric injury is provided, comprising the above-mentioned marine microalgae composition or the marine microalgae composition prepared by the above-mentioned preparation method.

[0066] In some specific embodiments, a pharmaceutically and / or food-acceptable dressing is also included.

[0067] In some specific embodiments, the pharmaceutically and / or food acceptable excipients;

[0068] In some specific embodiments, the pharmaceutically and / or food acceptable excipients are 16 to 23 parts.

[0069] Among them, the weight proportion of pharmaceutically and / or food acceptable excipients can be but not limited to 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts or 23 parts, and can also be any value between 16 and 23 parts, preferably 18 to 20 parts.

[0070] In some specific embodiments, the pharmaceutically and / or food acceptable excipient comprises at least one of maltodextrin, lactose or corn starch, preferably maltodextrin.

[0071] In some specific embodiments, the product is a liquid preparation or a solid preparation;

[0072] In some specific embodiments, the solid preparation is a solid beverage;

[0073] Preferably, the product comprises a medicine or a food;

[0074] Preferably, the food product is a special diet.

[0075] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0076] Example

[0077] A marine microalgae composition for preventing and / or improving acute gastric injury comprises the following components in parts by weight: 24 parts of wheat oligopeptides, 20 parts of Haematococcus pluvialis, 7 parts of dandelion, 6 parts of yam, 3.5 parts of orange peel, 3 parts of jujube, 1 part of white hyacinth bean, 1.6 parts of hawthorn, 1.3 parts of poria, 0.8 parts of chicken gizzard lining, 0.5 parts of malt, 1.5 parts of liquorice, 0.4 parts of radish seeds, 1 part of ginger, 6.5 parts of ginseng and 1.3 parts of raspberry.

[0078] Prepare according to the following steps: crush the above components into particles with a wall breaking machine to a particle size of about 0.1 mm.

[0079] The marine microalgae composition for preventing and / or improving acute gastric injury provided in Example 1 (hereinafter referred to as the marine microalgae composition) was selected for further experiments to verify its improvement effect on acute gastric injury.

[0080] Human dosage: 5g / time, 2 times / day, taken with warm water below 60℃.

[0081] Experiment 1 In vivo experiment:

[0082] 1. Experimental Animals

[0083] Thirty-six male SD rats (200 ± 20 g) were purchased from SBC (Beijing) Biotechnology Co., Ltd. (SCXK (Beijing) 2019-0010). The rats were housed in an environment with a temperature of 25 ± 0.5 °C and a humidity of 55 ± 5%, a 12-h light-dark cycle, and adaptive feeding for 1 week.

[0084] 2. Main reagents and instruments

[0085] Ranitidine hydrochloride (Shanghai McLean Biochemical Technology Co., Ltd., catalog number: B22260), anhydrous ethanol (Fuchen (Tianjin) Chemical Reagent Co., Ltd., catalog number: 20240318), universal tissue fixative (Servicebio, catalog number: G1101-500ML), rat interleukin 6 (IL-6) ELISA research kit (Jiangsu Enzyme Immunity Industrial Co., Ltd., catalog number: MM-0190R1), rat interleukin 10 (IL-10) ELISA research kit (Jiangsu Enzyme Immunity Industrial Co., Ltd., catalog number: MM-0195R1), catalase (CAT) assay kit (Nanjing Jiancheng Bioengineering Institute, catalog number: A007-1-1), trace reduced glutathione (GSH) assay kit (Nanjing Jiancheng Bioengineering Institute, catalog number: A006-2-1).

[0086] Microtome RM2235 (Shanghai Leica Instrument Co., Ltd.), electronic balance (Shanghai Precision Scientific Instrument Co., Ltd.), refrigerated centrifuge 5430R (Eppendorf), fluorescence microscope DM2000 (Shanghai Leica Instrument Co., Ltd.), and microplate reader RT-6100 (Raydo Life Sciences Co., Ltd.).

[0087] 3. Animal grouping and specimen collection.

[0088] Thirty-six SD rats were randomly divided into 6 groups after adaptive feeding, namely blank group, model group, positive drug group, low-dose experimental group, medium-dose experimental group and high-dose experimental group. Except for the blank group, the remaining rats were gavaged with 5 ml / kg of anhydrous ethanol to cause acute gastric injury, and the model was established 1 hour later.

[0089] Low-dose experimental group, medium-dose experimental group and high-dose experimental group: The marine microalgae composition provided in Example 1 was administered, with dosages of 900 mg / kg body weight for the low-dose group, 1800 mg / kg body weight for the medium-dose group, and 3600 mg / kg body weight for the high-dose group, once a day for 7 consecutive days.

[0090] Blank group and model group: an equal amount of normal saline was used instead.

[0091] Positive drug group: Ranitidine was used instead of the marine microalgae composition, and the dosage was 30 mg / kg body weight.

[0092] All rats were fasted but not watered for 24 hours after the last administration. Blood and stomach tissue were collected from the abdominal aorta.

[0093] 4. Macroscopic observation and histopathological analysis of gastric tissue.

[0094] 1) The gastric tissue was cut open along the greater curvature of the stomach, washed with saline, and the surface moisture was absorbed with filter paper. The gastric tissue sample was photographed. Then, a vernier caliper was used to measure the length and width of the lesion in the flat gastric tissue sample, and the degree of gastric mucosal damage was carefully observed.

[0095] Specific results such as Figure 1 As shown, A is the blank group, B is the model group, C is the positive drug group, D is the low-dose experimental group, E is the medium-dose experimental group, and F is the high-dose experimental group. The surface of the stomach tissue of the blank group rats was smooth, and mucus was attached, and the stomach wall was thick and elastic. Compared with the blank group rats, the stomach tissue of the rats in the model group injured with anhydrous ethanol showed multiple mucosal lesions, which were manifested as diffuse edema, thick linear bleeding, erosion, and ulcers along the long axis of the stomach, poor elasticity of the stomach wall and thin mucosal layer. After the marine microalgae composition and the positive drug ranitidine were administered to each experimental group and the positive drug group, the symptoms of thick linear bleeding, erosion, and ulcers in the gastric tissue were significantly reduced, the elasticity of the gastric wall increased, and the mucosa thickened.

[0096] 2) The gastric tissue near the gastric antrum was fixed in 4% paraformaldehyde for 24 hours, sliced ​​(5 μm thick), and embedded in paraffin. After dewaxing, the slices were stained with HE (hematoxylin and eosin) and PAS (Periodic Acid-Schiffstain) and observed under a microscope to analyze the damage of the gastric mucosa.

[0097] The results are as follows Figure 2 and Figure 3 As shown, A is a blank group, B is a model group, C is a positive drug group, D is a low-dose experimental group, E is a medium-dose experimental group, and F is a high-dose experimental group. HE staining results showed that compared with the blank group, the gastric mucosa of rats in the model group was degraded and deformed, the surface epithelial cells were destroyed, and inflammatory cells infiltrated the lamina propria, submucosal layer and serosal layer, indicating that ethanol caused gastric mucosal damage in rats. After administration of the marine microalgae composition and the positive drug ranitidine, each group showed a decrease in inflammatory cell infiltration and improvement in surface epithelial cell destruction. PAS staining results showed that after ethanol treatment, the glycoprotein content of the gastric mucosa decreased. After treatment with the positive drug ranitidine and different doses of marine microalgae compositions, the glycoprotein content gradually recovered, indicating that the marine microalgae composition can reduce inflammatory cell infiltration and protect gastric mucosal damage.

[0098] 3. Detection of interleukin-6 (IL-6) and interleukin-10 (IL-10) in rat serum.

[0099] The rat blood was centrifuged at 5000 rpm for 20 min at 4°C to separate the rat serum. The levels of 1L-6 and 1L-10 in the serum were detected by adding specific antibodies to react with the antigen and detecting with an enzyme marker.

[0100] The results are as follows Figure 4 Compared with the blank group, ### P < 0.001, # P<0.05, compared with the model group, ***P<0.001, **P<0.01, *P<0.05. Compared with the blank group, the anti-inflammatory cytokine IL-10 in the serum of the rats in the model group decreased, and the pro-inflammatory cytokine IL-6 increased, indicating that the stimulation of ethanol induced an inflammatory response. After treatment with different doses of marine microalgae composition and positive drug ranitidine, the anti-inflammatory cytokine I-10 increased, and the pro-inflammatory cytokine I-6 decreased, indicating that the marine microalgae composition can prevent gastric damage by alleviating inflammatory response.

[0101] 4. Detection of reduced glutathione (GSH) and catalase (CAT) in rat gastric tissue.

[0102] Cut the gastric tissue into pieces and put it into a homogenizer. Add 9 times the volume of physiological saline and put it in ice to fully grind it evenly to make a tissue homogenate. Centrifuge the homogenate at 3500rpm for 10 minutes at 4°C, and take part of the supernatant to determine its protein concentration. The levels of GSH and CAT in gastric tissue were detected by ELISA.

[0103] The results are as follows Figure 5 Compared with the blank group, ## P<0.01, # P<0.05, compared with the model group, ***P<0.001, **P<0.01, *P<0.05. Compared with the blank group, the levels of GSH and CAT in the model group decreased, indicating that ethanol induced oxidative stress in gastric tissue. After administration of the positive drug ranitidine and different doses of marine microalgae composition, the expression levels of GSH and CAT increased, indicating that the marine microalgae composition can prevent gastric damage by inhibiting oxidation.

[0104] Experiment 2 Network pharmacology analysis

[0105] 1. Prediction of the action targets of chemical components of marine microalgae compositions

[0106] The compound components of each drug in the marine microalgae composition were obtained from the TCMSP (https: / / www.tcmsp-e.com / # / home) and HERB (http: / / herb.ac.cn / ) databases, and the compound components were retrieved from the PubChem (https: / / pubchem.ncbi.nlm.nih.gov / ) database to obtain the Canonical SMILES structure. The Canonical SMILES of the compound components were input into the SwissTargetPrediction database (http: / / www.swisstargetprediction.ch / ), and the condition "Homo sapiens" was set to obtain the potential targets of the chemical components of the marine microalgae composition and predict them.

[0107] 2. Screening of gastric injury-related targets

[0108] Using "Gastric injury" as the keyword, we searched for targets related to gastric injury in the GeneCards database (https: / / www.genecards.org / ) and the OMIM database (https: / / omim.org / ), and the obtained gastric injury targets were merged and deduplicated.

[0109] 3. Intersection targets of marine microalgae composition and gastric injury

[0110] The screened drug targets and disease targets were input into the Microinformatics (www.bioinformatics.com.cn) webpage to draw a Venn diagram. Click the intersection area of ​​the Venn diagram to obtain the intersection target of the marine microalgae composition and gastric injury.

[0111] The compound components of 14 traditional Chinese medicines in the marine microalgae composition were searched through the TCMSP and HERB databases. 357 active ingredients were obtained by further screening through the TCMSP database with OB>30% and DL>0.18 as the screening conditions. A total of 1143 targets related to the marine microalgae composition were obtained using the SwissTargetPrediction platform. A total of 7221 gastric injury-related targets were obtained using the GeneCards database and the OMIM database with "Gastric injury" as the keyword. The results are as follows Figure 6 As shown, after taking the intersection of drug points and disease points, 877 targets for the marine microalgae composition to treat gastric injury were obtained.

[0112] 4. PPI network construction and analysis

[0113] The intersection targets were imported into the STRING (https: / / cn.string-db.org / ) website for protein interaction analysis, the species was selected as "Homo sapiens" and the "confidence" was adjusted to 0.7, the free targets were hidden, and the TSV format of the network was exported. The PPI network diagram was drawn using Cytoscape 3.9.1 software.

[0114] The 877 intersection targets were uploaded to the STRING database to obtain PPI network information, and the target protein PPI network was constructed using Cytoscape 3.9.1 software. Figure 7 As shown, the PPI network was analyzed using the MCODE module built into the Cytoscape3.9.1 software to obtain potential functional units, and TP53, EGFR, AKT1, STAT3, HSP90AA1IL6, TNF, BCL2, SRC, and HSP90AB1 were speculated to be the main targets.

[0115] 5. GO and KEGG enrichment analysis

[0116] The intersection target information was imported into the DAVID (https: / / david.ncifcrf.gov / ) platform for GO enrichment analysis and KEGG pathway enrichment analysis. GO analysis includes three levels: biological process (BP), molecular function (MF), and cellular component (CC). The results of GO enrichment analysis and KEGG enrichment analysis were obtained and plotted into bar charts and bubble charts using the microbial information platform.

[0117] The potential targets of marine microalgae composition for treating gastric injury were input into David platform for GO annotation analysis and KEGG pathway analysis. "Homosapiens" was selected, and P<0.05 was used as the screening condition. A total of 1812 entries were obtained, including 1351 BP entries, 137 CC entries, and 324 MF entries. They were sorted according to the order of P value, and the top 15 pathways of each category were selected for visualization analysis on the Weishengxin website. The results are shown in Figure 8 and Fig. 9As shown in the figure, the GO analysis results showed that BP mainly included positive regulation of nitric oxide biosynthesis, phosphorylation, negative regulation of gene expression, etc., CC mainly included plasma membrane, cytoplasmic perinuclear region, mitochondria, etc., and MF mainly included same protein binding, enzyme binding, nitric oxide synthase regulator activity, etc. The results of KEGG pathway enrichment analysis showed that statistically significant pathways were selected, and a total of 199 pathways were obtained. According to the P value, the top 30 pathways were visualized and analyzed on the Microscientific Information website. The larger the node, the more enriched genes. The enriched pathways mainly involved cancer pathways, lipid and atherosclerosis pathways, calcium signaling pathways, MAPK signaling pathways, etc.

[0118] 6. Construction of drug-active ingredient-disease-target network

[0119] Using CytoScape3.9.1 software, the core targets and main active ingredients were predicted based on the analysis results of potential targets of marine microalgae composition drug ingredients for improving gastric injury. Drugs, active ingredients, diseases and targets were imported into Cytoscape3.9.1 to construct a network diagram of marine microalgae composition drug-active ingredient-disease-target.

[0120] The results are as follows Fig.10 As shown in the figure, according to the results of topoisomerization analysis and the ranking of drugs according to degree values, it was shown that licorice, tangerine peel, hawthorn, malt and yam had relatively high activities, and their active ingredients that may play a role in efficacy were Glypallichalcone, tangeretin, linolenic acid, Kadsurenone, Chlorogenin and a-tocopheryl quinone, which indicated that the marine microalgae composition mainly played a role in preventing acute gastric injury through the above-mentioned active ingredients.

[0121] 7. Statistical analysis

[0122] GraphPad Prism9 (GraphPad, USA) software was used for statistical analysis of the entire database, and the results were expressed as mean + standard deviation (SD). In the case of comparison between two groups, independent sample t test was used, and p < 0.05 was considered statistically significant.

[0123] The experimental results show that the marine microalgae composition has an improvement effect on ethanol-induced acute gastric injury in rats. Its effect is achieved by inhibiting inflammatory response, reducing oxidative stress, and maintaining the integrity of the gastric mucus barrier. At the same time, network pharmacology results show that the marine microalgae composition mainly prevents acute gastric injury through active ingredients such as Glypallichalcone, tangeretin, linolenicacid, Kadsurenone, Chlorogenin, and a-tocopherylquinone, and prevents gastric injury by acting on core targets such as TP53, EGFR, AKT1, STAT3, HSP90AA1, IL6, TNF, BCL2, SRC, and HSP90AB1, regulating inflammatory signals such as MAPK and P13K-Akt signaling pathways.

[0124] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A marine microalgae composition for preventing and / or improving acute gastric injury, characterized in that: The invention comprises the following components in parts by weight: 20-26 parts of wheat oligopeptide, 15-24 parts of microalgae, 5-10 parts of dandelion, 4-8 parts of yam, 1-5 parts of orange peel, 2-4 parts of jujube, 0.5-1.5 parts of white hyacinth bean, 1-2 parts of hawthorn, 0.5-2 parts of poria, 0.4-1.2 parts of chicken gizzard lining, 0.3-0.8 parts of malt, 1-2 parts of liquorice, 0.2-0.6 parts of radish seeds, 0.5-1.5 parts of ginger, 5-8 parts of ginseng and 0.4-2 parts of raspberry.

2. The marine microalgae composition according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 24 parts of wheat oligopeptides, 20 parts of microalgae, 7 parts of dandelion, 6 parts of yam, 3.5 parts of orange peel, 3 parts of jujube, 1 part of white hyacinth bean, 1.6 parts of hawthorn, 1.3 parts of poria, 0.8 parts of chicken gizzard lining, 0.5 parts of malt, 1.5 parts of liquorice, 0.4 parts of radish seeds, 1 part of ginger, 6.5 parts of ginseng and 1.3 parts of raspberry.

3. The marine microalgae composition according to claim 2, characterized in that: The microalgae is at least one of Dunaliella salina, Pseudochlorophyll, Haematococcus pluvialis, Spirulina or Chlorella.

4. The method for preparing the marine microalgae composition according to any one of claims 1 to 3, characterized in that: The method comprises mixing various components according to the formula amount to prepare the marine microalgae composition.

5. The preparation method according to claim 4, characterized in that: Before mixing, the components are crushed and broken into powder; Preferably, the particle size of the powder is 0.01-0.3 mm.

6. Use of the marine microalgae composition according to any one of claims 1 to 3 or the marine microalgae composition prepared by the preparation method according to claim 4 or 5 in preparing a product for preventing and / or improving acute gastric injury.

7. A product for preventing acute gastric injury, characterized in that: The invention comprises the marine microalgae composition according to any one of claims 1 to 3 or the marine microalgae composition prepared by the preparation method according to claim 4 or 5.

8. The product according to claim 7, characterized in that Pharmaceutically and / or food-acceptable dressings are also included.

9. The product according to claim 8, characterized in that The pharmaceutically and / or food acceptable excipients; Preferably, the pharmaceutically and / or food acceptable excipients are 16 to 23 parts, preferably 18 to 20 parts; Preferably, the pharmaceutically and / or food acceptable excipient comprises at least one of maltodextrin, lactose or corn starch, preferably maltodextrin.

10. The product according to claim 9, characterized in that The product is a liquid preparation or a solid preparation; Preferably, the solid preparation is a solid beverage; Preferably, the product comprises a medicine or a food; Preferably, the food product is a special diet.

Images